Decoy Therapeutics Inc. announced plans to advance its pipeline of peptide conjugate therapeutics using its proprietary IMP3ACT platform, with a focus on making countermeasures for emerging pathogens accessible to low- and middle-income countries. The company expects to file an Investigational New Drug $(IND)$ application with the U.S. FDA for its lead asset, a pan-coronavirus antiviral, within the next 12 months. Additionally, Decoy is progressing on other programs, including a broad-acting antiviral for flu, COVID-19, and RSV, as well as a peptide drug conjugate targeting GI cancers. The company’s intranasal pan-coronavirus fusion inhibitor, which demonstrates the IMP3ACT platform’s design-for-manufacturing capability, will be used to validate Decoy’s new distributed manufacturing network. The results of these research and development efforts will be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE61689) on January 13, 2026, and is solely responsible for the information contained therein.